Logo image of CDT

CONDUIT PHARMACEUTICALS INC (CDT) Stock Fundamental Analysis

NASDAQ:CDT - Nasdaq - US20678X1063 - Common Stock

0.0675  0 (-6.25%)

After market: 0.07 +0 (+3.7%)

Fundamental Rating

0

CDT gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of CDT have multiple concerns. CDT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CDT had negative earnings in the past year.
In the past year CDT has reported a negative cash flow from operations.
CDT Yearly Net Income VS EBIT VS OCF VS FCFCDT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -2M -4M -6M

1.2 Ratios

CDT has a worse Return On Assets (-454.96%) than 98.21% of its industry peers.
Industry RankSector Rank
ROA -454.96%
ROE N/A
ROIC N/A
ROA(3y)-2.37%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CDT Yearly ROA, ROE, ROICCDT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 50 -50 100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CDT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDT Yearly Profit, Operating, Gross MarginsCDT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for CDT has been increased compared to 1 year ago.
The debt/assets ratio for CDT is higher compared to a year ago.
CDT Yearly Shares OutstandingCDT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M
CDT Yearly Total Debt VS Total AssetsCDT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

CDT has an Altman-Z score of -30.44. This is a bad value and indicates that CDT is not financially healthy and even has some risk of bankruptcy.
CDT has a Altman-Z score of -30.44. This is amonst the worse of the industry: CDT underperforms 96.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -30.44
ROIC/WACCN/A
WACCN/A
CDT Yearly LT Debt VS Equity VS FCFCDT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

CDT has a Current Ratio of 0.12. This is a bad value and indicates that CDT is not financially healthy enough and could expect problems in meeting its short term obligations.
CDT's Current ratio of 0.12 is on the low side compared to the rest of the industry. CDT is outperformed by 98.21% of its industry peers.
A Quick Ratio of 0.12 indicates that CDT may have some problems paying its short term obligations.
With a Quick ratio value of 0.12, CDT is not doing good in the industry: 98.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
CDT Yearly Current Assets VS Current LiabilitesCDT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 1M 2M 3M 4M 5M

More info and screens

0

3. Growth

3.1 Past

CDT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1803.19%.
EPS 1Y (TTM)-1803.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-346.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CDT Yearly Revenue VS EstimatesCDT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
CDT Yearly EPS VS EstimatesCDT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDT Price Earnings VS Forward Price EarningsCDT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDT Per share dataCDT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CDT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONDUIT PHARMACEUTICALS INC

NASDAQ:CDT (1/21/2025, 8:00:02 PM)

After market: 0.07 +0 (+3.7%)

0.0675

0 (-6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners3.15%
Inst Owner Change3.58%
Ins Owners4.94%
Ins Owner Change-55.92%
Market Cap8.09M
AnalystsN/A
Price TargetN/A
Short Float %5.42%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0
BVpS-0.08
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -454.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.37%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z -30.44
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1803.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-346.85%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-433.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-489.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-489.69%
OCF growth 3YN/A
OCF growth 5YN/A